


APPLICANT FACSIMILE OF FORM PTO-1449 REV 7-80	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO MBI-008	SERIAL NO. 09/512 581
LIST OF PUBLICATIONS CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT Ana M. Soto et al.	
		FILING DATE February 24, 2000	

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS


	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
SR	C1 WO 9731531	9/97	PCT	—	—	—	—

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

SR	C2	DATABASE EMBL NUCLEOTIDE AND PROTEIN SEQUENCES September 11, 1996, AC=U50553. Human BRCA2 region;
SR	C3	DATABASE EMBL NUCLEOTIDE AND PROTEIN SEQUENCES January 30, 1997, AC=Z84572. Human DNA sequence from PAC 49J10, BRCA2 gene region chromosome 13q12-13 contains ESTs;
SR	C4	DATABASE EMBL NUCLEOTIDE AND PROTEIN SEQUENCES November 1, 1999, AC=Q9Y215 KIAA0979 PROTIEN (FRAGMENT);
SR	C5	DATABASE EMBL NUCLEOTIDE AND PROTEIN SEQUENCES January 25, 2000, AC=AL137201 Novel human gene mapping to chromosome 13.
SR	C6	DATABASE EMBL NUCLEOTIDE AND PROTEIN SEQUENCES March 31, 1999, AC=U95825, Human androgen-induced prostate proliferative shutoff associated protein (AS3) mRNA;
Examiner <i>J. Raulson</i>		Date Considered <i>11/14/01</i>
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

RECEIVED
 MAR 13 2001
 TECH CENTER 1600/2600

APPLICANT FACSIMILE OF FORM PTO-1449 REV 7-80	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO MBI-008	SERIAL NO. 09/512,581
LIST OF PUBLICATIONS CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT Ana M. Soto et al.	
		FILING DATE February 24, 2000	GROUP



U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

SR	A1	Denison SH, et al. Mutation in the bimD gene of <i>Aspergillus nidulans</i> confers a conditional mitotic block and sensitivity to DNA damaging agents. <i>Genetics</i> . 1993 Aug;134(4):1085-96;
SR	A2	Geck P, et al. Expression of novel genes linked to the androgen-induced, proliferative shutoff in prostate cancer cells. <i>J Steroid Biochem Mol Biol</i> . 1997 Nov-Dec;63(4-6):211-8;
SR	A3	Geck P, et al. Early gene expression during androgen-induced inhibition of proliferation of prostate cancer cells: a new suppressor candidate on chromosome 13, in the BRCA2-Rb1 locus. <i>J Steroid Biochem Mol Biol</i> . 1999 Jan;68(1-2):41-50;
SR	A4	Koch C, et al. A role for the transcription factors Mbp1 and Swi4 in progression from G1 to S phase. <i>Science</i> . 1993 Sep 17;261(5128):1551-7;
SR	A5	Sadar MD, et al. Prostate cancer: molecular biology of early progression to androgen independence. <i>Endocr Relat Cancer</i> . 1999 Dec;6(4):487-502;
SR	A6	Soto AM, et al. Variants of the human prostate LNCaP cell line as tools to study discrete components of the androgen-mediated proliferative response. <i>Oncol Res</i> . 1995;7(10-11):545-58;
SR	A7	Soto AM, et al. The role of estrogens on the proliferation of human breast tumor cells (MCF-7). <i>J Steroid Biochem</i> . 1985 Jul;23(1):87-94;
SR	A8	Thiessen EU. Concerning a familial association between breast cancer and both prostatic and uterine malignancies. <i>Cancer</i> . 1974 Oct;34(4):1102-7;
Examiner <i>J. Ramirez</i>		Date Considered <i>11/14/01</i>
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

[illegible]

Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.